| 货号 | 9002910-25mg |
| 描述 | (+)-JQ1 (free acid) is an inhibitor of bromodomain and extra terminal domain (BET) family proteins (Kds = 128, 59.5, 49.0, and 190 nM for JQ1 binding to bromodomains of BRD2, BRD3, BRD4, and BRDT, respectively), blocking their interaction with acetylated histones.1,2 Enantiomerically pure (+)-JQ1 (Item No. 11187) binds to BRD4 bromodomains 1 and 2 with Kd values of ~50 and 90 nM, respectively, whereas the (−)-JQ1 (Item No. 11232) stereoisomer has no appreciable affinity to BET bromodomains.1 JQ1 has been used as a chemical probe to investigate the role of BET bromodomains in the transcriptional regulation of oncogenesis.1,2,3,4,5 See the Structural Genomics Consortium (SGC) website for more information. |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Filippakopoulos, P.,Qi, J.,Picaud, S., et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067-1073 (2010). 2.Dawson, M.A.,Kouzarides, T. and Huntly, B.J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367(7), 647-657 (2012). 3.Delmore, J.E.,Issa, G.C.,Lemieux, M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011). 4.Mertz, J.A.,Conery, A.R.,Bryant, B.M., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108(40), 16669-16674 (2011). 5.Dawson, M.A.,Prinjha, R.K.,Dittmann, A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 400.9 |
| 分子式 | C19H17ClN4O2S |
| CAS号 | 202592-23-2 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |